MedDataX Logo

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT ID: NCT06623422

Last Updated: 2025-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

680 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-21

Study Completion Date

2038-01-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Programmed Cell Death-1 (PD1, PD-1) Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1) Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) Individualized neoantigen therapy (INT)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pembrolizumab + Intismeran autogene

For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type BIOLOGICAL

IV Infusion

Cisplatin

Intervention Type DRUG

IV infusion

Carboplatin

Intervention Type DRUG

IV infusion

Pemetrexed

Intervention Type DRUG

IV infusion

Gemcitabine

Intervention Type DRUG

IV infusion

Paclitaxel

Intervention Type DRUG

IV infusion

Intismeran autogene

Intervention Type BIOLOGICAL

IM injection

Pembrolizumab + Placebo

For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).

Group Type ACTIVE_COMPARATOR

Pembrolizumab

Intervention Type BIOLOGICAL

IV Infusion

Cisplatin

Intervention Type DRUG

IV infusion

Carboplatin

Intervention Type DRUG

IV infusion

Pemetrexed

Intervention Type DRUG

IV infusion

Gemcitabine

Intervention Type DRUG

IV infusion

Paclitaxel

Intervention Type DRUG

IV infusion

Placebo

Intervention Type OTHER

IM injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pembrolizumab

IV Infusion

Intervention Type BIOLOGICAL

Cisplatin

IV infusion

Intervention Type DRUG

Carboplatin

IV infusion

Intervention Type DRUG

Pemetrexed

IV infusion

Intervention Type DRUG

Gemcitabine

IV infusion

Intervention Type DRUG

Paclitaxel

IV infusion

Intervention Type DRUG

Intismeran autogene

IM injection

Intervention Type BIOLOGICAL

Placebo

IM injection

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-3475 KEYTRUDA® Platinol® Platinol®-AQ Paraplatin® Alimta® Gemzar Taxol® Onxol® mRNA-4157 V940

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has histologically/cytologically confirmed diagnosis of previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) \[American Joint Committee on Cancer (AJCC) 8th Edition\]
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention
* Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be eligible
* Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations \[eg, DEL19 or L858R\])
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Exclusion Criteria

* Diagnosis of SCLC or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large-cell components, or a sarcomatoid carcinoma, or a pancoast tumor
* Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements
* Received prior neoadjuvant therapy for their current NSCLC diagnosis
* Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein \[CTLA-4\], OX-40, CD137)
* Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol
* Received prior treatment with a cancer vaccine
* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ModernaTX, Inc.

INDUSTRY

Sponsor Role collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner MD Anderson Cancer Center ( Site 0181)

Gilbert, Arizona, United States

Site Status RECRUITING

Providence St. Jude Medical Center ( Site 0106)

Fullerton, California, United States

Site Status RECRUITING

VA Long Beach Healthcare System ( Site 0199)

Long Beach, California, United States

Site Status RECRUITING

USC Norris Comprehensive Cancer Center ( Site 0205)

Los Angeles, California, United States

Site Status RECRUITING

UCSF Medical Center at Mission Bay ( Site 0178)

San Francisco, California, United States

Site Status RECRUITING

UCHealth Memorial Hospital Central ( Site 0125)

Colorado Springs, Colorado, United States

Site Status RECRUITING

Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)

Greeley, Colorado, United States

Site Status RECRUITING

Centura Health - St. Anthony North Health Campus ( Site 0189)

Westminster, Colorado, United States

Site Status RECRUITING

Yale University School of Medicine ( Site 0201)

New Haven, Connecticut, United States

Site Status RECRUITING

Eastern CT Hematology & Oncology Associates ( Site 0202)

Norwich, Connecticut, United States

Site Status RECRUITING

The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156)

Fort Lauderdale, Florida, United States

Site Status RECRUITING

Beacon Cancer Care ( Site 0127)

Post Falls, Idaho, United States

Site Status RECRUITING

The University of Chicago Medical Center ( Site 0118)

Chicago, Illinois, United States

Site Status RECRUITING

Maryland Oncology Hematology (MOH) ( Site 8102)

Rockville, Maryland, United States

Site Status RECRUITING

Massachusetts General Hospital ( Site 0136)

Boston, Massachusetts, United States

Site Status RECRUITING

Dana Farber Cancer Hospital ( Site 0155)

Boston, Massachusetts, United States

Site Status RECRUITING

Ellis Fischel Cancer Center ( Site 0133)

Columbia, Missouri, United States

Site Status RECRUITING

Lake Regional Hospital-Cancer Center ( Site 0123)

Osage Beach, Missouri, United States

Site Status RECRUITING

Roswell Park Cancer Institute ( Site 0184)

Buffalo, New York, United States

Site Status RECRUITING

Hematology-Oncology Associates of CNY ( Site 0164)

East Syracuse, New York, United States

Site Status RECRUITING

The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216)

New York, New York, United States

Site Status RECRUITING

Icahn School of Medicine at Mount Sinai ( Site 0116)

New York, New York, United States

Site Status RECRUITING

Memorial Sloan Kettering Cancer Center ( Site 0137)

New York, New York, United States

Site Status RECRUITING

SUNY Upstate Cancer Center ( Site 0140)

Syracuse, New York, United States

Site Status RECRUITING

Montefiore Medical Center ( Site 0160)

The Bronx, New York, United States

Site Status RECRUITING

Westchester Medical Center ( Site 0196)

Valhalla, New York, United States

Site Status RECRUITING

University of Cincinnati Medical Center ( Site 0119)

Cincinnati, Ohio, United States

Site Status RECRUITING

St. Lukes Hospital and Health Network ( Site 0186)

Bethlehem, Pennsylvania, United States

Site Status RECRUITING

Thompson Cancer Survival Center ( Site 0168)

Knoxville, Tennessee, United States

Site Status RECRUITING

Texas Oncology - DFW ( Site 8103)

Dallas, Texas, United States

Site Status RECRUITING

Houston Methodist Cancer Center ( Site 0191)

Houston, Texas, United States

Site Status RECRUITING

MD Anderson Cancer Center ( Site 0150)

Houston, Texas, United States

Site Status RECRUITING

Memorial Hermann Cancer Center ( Site 0172)

Houston, Texas, United States

Site Status RECRUITING

O'Quinn Medical Tower at McNair Campus ( Site 0131)

Houston, Texas, United States

Site Status RECRUITING

The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148)

Tyler, Texas, United States

Site Status RECRUITING

Virginia Cancer Specialists ( Site 0167)

Fairfax, Virginia, United States

Site Status RECRUITING

Swedish Cancer Institute ( Site 0143)

Seattle, Washington, United States

Site Status RECRUITING

Virginia Mason Franciscan Health - St. Michael Cancer Center ( Site 0192)

Silverdale, Washington, United States

Site Status RECRUITING

CEMIC ( Site 2454)

Caba., Buenos Aires, Argentina

Site Status RECRUITING

Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2459)

Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina

Site Status RECRUITING

Fundacion Intecnus ( Site 2456)

Bariloche, Río Negro Province, Argentina

Site Status RECRUITING

Centro Médico IPAM ( Site 2452)

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Instituto Medico Especializado Alexander Fleming ( Site 2457)

Buenos Aires, , Argentina

Site Status RECRUITING

Instituto Oncologico de Cordoba -IONC ( Site 2455)

Córdoba, , Argentina

Site Status RECRUITING

Calvary Mater Newcastle ( Site 2106)

Waratah, New South Wales, Australia

Site Status RECRUITING

Tasman Oncology Research ( Site 2104)

Southport, Queensland, Australia

Site Status RECRUITING

Princess Alexandra Hospital ( Site 2102)

Wooloongabba, Queensland, Australia

Site Status RECRUITING

Grampians Health ( Site 2101)

Ballarat, Victoria, Australia

Site Status RECRUITING

One Clinical Research ( Site 2103)

Nedlands, Western Australia, Australia

Site Status RECRUITING

Cliniques Universitaires Saint-Luc ( Site 1203)

Brussels, Bruxelles-Capitale, Region de, Belgium

Site Status RECRUITING

Jessa Ziekenhuis ( Site 1204)

Hasselt, Limburg, Belgium

Site Status RECRUITING

UZ Gent ( Site 1201)

Ghent, Oost-Vlaanderen, Belgium

Site Status RECRUITING

CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502)

Fortaleza, Ceará, Brazil

Site Status RECRUITING

Liga Norte Riograndense Contra o Cancer ( Site 2513)

Natal, Rio Grande do Norte, Brazil

Site Status RECRUITING

Hospital Tacchini ( Site 2506)

Bento Gonçalves, Rio Grande do Sul, Brazil

Site Status RECRUITING

Hospital de Clínicas de Passo Fundo ( Site 2504)

Passo Fundo, Rio Grande do Sul, Brazil

Site Status RECRUITING

Hospital Moinhos de Vento ( Site 2510)

Porto Alegre, Rio Grande do Sul, Brazil

Site Status RECRUITING

Hospital Nossa Senhora Da Conceicao ( Site 2512)

Porto Alegre, Rio Grande do Sul, Brazil

Site Status RECRUITING

Instituto de Oncologia Saint Gallen ( Site 2507)

Santa Cruz do Sul, Rio Grande do Sul, Brazil

Site Status RECRUITING

Hospital de Amor - Barretos ( Site 2511)

Barretos, São Paulo, Brazil

Site Status RECRUITING

Instituto Nacional de Câncer - INCA ( Site 2501)

Rio de Janeiro, , Brazil

Site Status RECRUITING

MBAL Uni Hospital ( Site 1253)

Panagyurishte, Pazardzhik, Bulgaria

Site Status RECRUITING

MHAT - Heart and Brain ( Site 1252)

Pleven, , Bulgaria

Site Status RECRUITING

Queen Elizabeth II Health Sciences Centre ( Site 1101)

Halifax, Nova Scotia, Canada

Site Status RECRUITING

Hamilton Health Sciences - Juravinski Site ( Site 1104)

Hamilton, Ontario, Canada

Site Status RECRUITING

Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1105)

Kingston, Ontario, Canada

Site Status RECRUITING

Lakeridge Health ( Site 1107)

Oshawa, Ontario, Canada

Site Status RECRUITING

Sunnybrook Research Institute ( Site 1106)

Toronto, Ontario, Canada

Site Status RECRUITING

McGill University Health Centre ( Site 1103)

Montreal, Quebec, Canada

Site Status RECRUITING

IUCPQ ( Site 1112)

Québec, Quebec, Canada

Site Status RECRUITING

Orlandi Oncologia ( Site 2555)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

FALP ( Site 2551)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Clínica RedSalud Vitacura ( Site 2556)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Bradfordhill ( Site 2552)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

ONCOCENTRO APYS ( Site 2554)

Viña del Mar, Región de Valparaíso, Chile

Site Status RECRUITING

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2603)

Bogotá, Bogota D.C., Colombia

Site Status RECRUITING

Hospital Universitario San Ignacio ( Site 2610)

Bogotá, Bogota D.C., Colombia

Site Status RECRUITING

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 2604)

Bogotá, Bogota D.C., Colombia

Site Status RECRUITING

IMAT S.A.S ( Site 2602)

Montería, Departamento de Córdoba, Colombia

Site Status RECRUITING

Oncologos del Occidente ( Site 2608)

Pereira, Risaralda Department, Colombia

Site Status RECRUITING

Fundacion Valle del Lili- CIC ( Site 2601)

Cali, Valle del Cauca Department, Colombia

Site Status RECRUITING

Oulun yliopistollinen sairaala ( Site 1301)

Oulu, Northern Savonia, Finland

Site Status RECRUITING

Turku University Hospital ( Site 1303)

Turku, Southwest Finland, Finland

Site Status RECRUITING

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau ( Site 1354)

Tours, Centre-Val de Loire, France

Site Status RECRUITING

CHU Besançon ( Site 1358)

Besançon, Franche-Comte, France

Site Status RECRUITING

Institut De Cancerologie De L Ouest ( Site 1357)

Saint-Herblain, Loire-Atlantique, France

Site Status RECRUITING

Institut Cœur Poumon -CHU Lille ( Site 1352)

Lille, Nord, France

Site Status RECRUITING

CENTRE LEON BERARD ( Site 1351)

Lyon, Rhone, France

Site Status RECRUITING

Robert-Bosch-Krankenhaus ( Site 1401)

Stuttgart, Baden-Wurttemberg, Germany

Site Status RECRUITING

Klinikverbund Allgäu gGmbH ( Site 1408)

Kempten (Allgäu), Bavaria, Germany

Site Status RECRUITING

UKGM Gießen/Marburg ( Site 1404)

Giessen, Hesse, Germany

Site Status RECRUITING

St.-Antonius-Hospital ( Site 1411)

Eschweiler, North Rhine-Westphalia, Germany

Site Status RECRUITING

Universitätsklinikum Münster - Albert Schweitzer Campus ( Site 1405)

Münster, North Rhine-Westphalia, Germany

Site Status RECRUITING

Marienhaus Klinikum Mainz ( Site 1403)

Mainz, Rhineland-Palatinate, Germany

Site Status RECRUITING

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1452)

Pátrai, Achaia, Greece

Site Status RECRUITING

Errikos Dunant Hospital Center ( Site 1457)

Athens, Attica, Greece

Site Status RECRUITING

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1451)

Athens, Attica, Greece

Site Status RECRUITING

Metropolitan Hospital ( Site 1459)

Athens, Attica, Greece

Site Status RECRUITING

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1460)

Chaïdári, Attica, Greece

Site Status RECRUITING

University General Hospital of Herakleion ( Site 1458)

Heraklion, Irakleio, Greece

Site Status RECRUITING

University General Hospital of Larissa-Oncology Clinic ( Site 1453)

Larissa, Thessaly, Greece

Site Status RECRUITING

Papageorgiou General Hospital of Thessaloniki ( Site 1454)

Thessaloniki, , Greece

Site Status RECRUITING

Fejér Megyei Szent György Egyetemi Oktató Kórház ( Site 1506)

Székesfehérvár, Fejér, Hungary

Site Status RECRUITING

Petz Aladár Megyei Oktató Kórház ( Site 1502)

Győr, Győr-Moson-Sopron, Hungary

Site Status RECRUITING

Debreceni Egyetem Altalanos Orvostudomanyi Kar Tudogyogyaszati Tanszek ( Site 1508)

Debrecen, Hajdú-Bihar, Hungary

Site Status RECRUITING

Mátrai Gyógyintézet ( Site 1504)

Mátraháza, Heves County, Hungary

Site Status RECRUITING

Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1505)

Törökbálint, Pest County, Hungary

Site Status RECRUITING

Somogy Vármegyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1507)

Kaposvár, Somogy County, Hungary

Site Status RECRUITING

Orszagos Koranyi Pulmonologiai Intezet ( Site 1501)

Budapest, , Hungary

Site Status RECRUITING

Cork University Hospital ( Site 1553)

Cork, , Ireland

Site Status RECRUITING

Tallaght University Hospital ( Site 1551)

Dublin, , Ireland

Site Status RECRUITING

Rambam Health Care Campus ( Site 1603)

Haifa, , Israel

Site Status RECRUITING

Shaare Zedek Medical Center ( Site 1601)

Jerusalem, , Israel

Site Status RECRUITING

Hadassah Medical Center ( Site 1605)

Jerusalem, , Israel

Site Status RECRUITING

Meir Medical Center ( Site 1606)

Kfar Saba, , Israel

Site Status RECRUITING

Sheba Medical Center ( Site 1602)

Ramat Gan, , Israel

Site Status RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1653)

Rome, Lazio, Italy

Site Status RECRUITING

Fondazione Policlinico Universitario Campus Bio-Medico ( Site 1660)

Rome, Roma, Italy

Site Status RECRUITING

Istituto Nazionale Tumori Regina Elena ( Site 1651)

Rome, Roma, Italy

Site Status RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1656)

Milan, , Italy

Site Status RECRUITING

IEO Istituto Europeo di Oncologia ( Site 1655)

Milan, , Italy

Site Status RECRUITING

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1657)

Napoli, , Italy

Site Status RECRUITING

Centro Ricerche Cliniche di Verona ( Site 1659)

Verona, , Italy

Site Status RECRUITING

Hospital of the University of Occupational and Environmental Health, Japan ( Site 1166)

Kitakyushu, Fukuoka, Japan

Site Status RECRUITING

St. Marianna University Hospital ( Site 1159)

Kawasaki, Kanagawa, Japan

Site Status RECRUITING

Kanagawa Cancer Center ( Site 1158)

Yokohama, Kanagawa, Japan

Site Status RECRUITING

Kindai University Hospital ( Site 1162)

Sakai, Osaka, Japan

Site Status RECRUITING

Shizuoka Cancer Center ( Site 1160)

Sunto-gun, Shizuoka, Japan

Site Status RECRUITING

Dokkyo Medical University Hospital ( Site 1152)

Shimotsuga-gun, Tochigi, Japan

Site Status RECRUITING

National Cancer Center Hospital ( Site 1156)

Chūō, Tokyo, Japan

Site Status RECRUITING

Tokyo Medical University Hospital ( Site 1157)

Shinjuku, Tokyo, Japan

Site Status RECRUITING

Chiba University Hospital ( Site 1154)

Chiba, , Japan

Site Status RECRUITING

National Hospital Organization Kyushu Cancer Center ( Site 1167)

Fukuoka, , Japan

Site Status RECRUITING

Fukushima Medical University Hospital ( Site 1151)

Fukushima, , Japan

Site Status RECRUITING

Hiroshima University Hospital ( Site 1165)

Hiroshima, , Japan

Site Status RECRUITING

Okayama University Hospital ( Site 1164)

Okayama, , Japan

Site Status RECRUITING

Osaka International Cancer Institute ( Site 1161)

Osaka, , Japan

Site Status RECRUITING

Wakayama Medical University Hospital ( Site 1163)

Wakayama, , Japan

Site Status RECRUITING

Radboudumc ( Site 1706)

Nijmegen, Gelderland, Netherlands

Site Status RECRUITING

Maastricht UMC+ ( Site 1705)

Maastricht, Limburg, Netherlands

Site Status RECRUITING

Jeroen Bosch Hospital ( Site 1701)

's-Hertogenbosch, North Brabant, Netherlands

Site Status RECRUITING

Medisch Centrum Leeuwarden ( Site 1702)

Leeuwarden, Provincie Friesland, Netherlands

Site Status RECRUITING

Dunedin Hospital ( Site 2202)

Dunedin, Otago, New Zealand

Site Status RECRUITING

Waikato Hospital ( Site 2204)

Hamilton, Waikato Region, New Zealand

Site Status RECRUITING

Aliada ( Site 2753)

Lima, , Peru

Site Status RECRUITING

Clínica Internacional - Sede San Borja ( Site 2752)

Lima, , Peru

Site Status RECRUITING

Detecta Clínica ( Site 2751)

Lima, , Peru

Site Status RECRUITING

Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1763)

Poznan, Greater Poland Voivodeship, Poland

Site Status RECRUITING

Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 1756)

Krakow, Lesser Poland Voivodeship, Poland

Site Status RECRUITING

Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 1764)

Warsaw, Masovian Voivodeship, Poland

Site Status RECRUITING

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1759)

Przemyśl, Podkarpackie Voivodeship, Poland

Site Status RECRUITING

Uniwersyteckie Centrum Kliniczne ( Site 1758)

Gdansk, Pomeranian Voivodeship, Poland

Site Status RECRUITING

Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie ( Site 1760)

Olsztyn, Warmian-Masurian Voivodeship, Poland

Site Status RECRUITING

Swietokrzyskie Centrum Onkologii. ( Site 1754)

Kielce, Świętokrzyskie Voivodeship, Poland

Site Status RECRUITING

Centrul Medical Medicover Victoria ( Site 1802)

Bucharest, București, Romania

Site Status RECRUITING

Institutul Regional de Oncologie ( Site 1804)

Iași, , Romania

Site Status RECRUITING

National Cancer Centre Singapore ( Site 2251)

Singapore, Central Singapore, Singapore

Site Status RECRUITING

Tan Tock Seng Hospital ( Site 2252)

Singapore, Central Singapore, Singapore

Site Status RECRUITING

National Cancer Center ( Site 2305)

Goyang-si, Kyonggi-do, South Korea

Site Status RECRUITING

The Catholic University of Korea St. Vincent s Hospital ( Site 2301)

Suwon, Kyonggi-do, South Korea

Site Status RECRUITING

Ajou University Hospital ( Site 2306)

Suwon, Kyonggi-do, South Korea

Site Status RECRUITING

Seoul National University Hospital ( Site 2303)

Seoul, , South Korea

Site Status RECRUITING

Severance Hospital Yonsei University Health System ( Site 2302)

Seoul, , South Korea

Site Status RECRUITING

Samsung Medical Center ( Site 2304)

Seoul, , South Korea

Site Status RECRUITING

Seoul St. Mary's Hospital ( Site 2307)

Seoul, , South Korea

Site Status RECRUITING

Hospital Insular de Gran Canaria ( Site 1911)

Canarias, Canary Islands, Spain

Site Status RECRUITING

Hospital Clinic de Barcelona ( Site 1919)

Barcelona, Catalonia, Spain

Site Status RECRUITING

Complejo Hospitalario Universitario A Coruna ( Site 1916)

A Coruña, La Coruna, Spain

Site Status RECRUITING

Hospital Universitario Quiron Madrid ( Site 1913)

Pozuelo de Alarcón, Madrid, Spain

Site Status RECRUITING

Hospital Universitari Vall D Hebron ( Site 1910)

Barcelona, , Spain

Site Status RECRUITING

Hospital General Universitario Gregorio Maranon ( Site 1912)

Madrid, , Spain

Site Status RECRUITING

Hospital Quiron Malaga ( Site 1914)

Málaga, , Spain

Site Status RECRUITING

Karolinska Universitetssjukhuset Solna ( Site 1951)

Stockholm, Stockholm County, Sweden

Site Status RECRUITING

Chung Shan Medical University Hospital ( Site 2351)

Taichung, , Taiwan

Site Status RECRUITING

China Medical University Hospital ( Site 2358)

Taichung, , Taiwan

Site Status RECRUITING

National Cheng Kung University Hospital ( Site 2354)

Tainan, , Taiwan

Site Status RECRUITING

National Taiwan University Cancer Center (NTUCC) ( Site 2360)

Taipei, , Taiwan

Site Status RECRUITING

Mackay Memorial Hospital ( Site 2355)

Taipei, , Taiwan

Site Status RECRUITING

Taipei Medical University Hospital ( Site 2352)

Taipei, , Taiwan

Site Status RECRUITING

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359)

Taipei, , Taiwan

Site Status RECRUITING

Taipei Veterans General Hospital ( Site 2357)

Taipei, , Taiwan

Site Status RECRUITING

Chang Gung Memorial Hospital ( Site 2361)

Taoyuan District, , Taiwan

Site Status RECRUITING

Hacettepe Universite Hastaneleri ( Site 2001)

Sıhhiye, Ankara, Turkey (Türkiye)

Site Status RECRUITING

Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2006)

Adapazarı, Sakarya, Turkey (Türkiye)

Site Status RECRUITING

Namık Kemal University Medical Faculty ( Site 2007)

Tekirdağ, Tekirdas, Turkey (Türkiye)

Site Status RECRUITING

Ankara Bilkent Sehir Hastanesi ( Site 2002)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 2003)

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Karadeniz Technical University ( Site 2008)

Trabzon, , Turkey (Türkiye)

Site Status RECRUITING

Bristol Haematology and Oncology Centre ( Site 2072)

Bristol, Bristol, City of, United Kingdom

Site Status RECRUITING

ROYAL MARSDEN HOSPITAL (CHELSEA)-Lung Unit ( Site 2075)

London, Kensington and Chelsea, United Kingdom

Site Status RECRUITING

St Bartholomews Hospital ( Site 2052)

London, London, City of, United Kingdom

Site Status RECRUITING

Royal Free Hospital ( Site 2074)

London, London, City of, United Kingdom

Site Status RECRUITING

Guys Hospital ( Site 2057)

London, London, City of, United Kingdom

Site Status RECRUITING

Royal Marsden Hospital (Sutton) ( Site 2076)

London, London, City of, United Kingdom

Site Status RECRUITING

Nottingham City Hospital ( Site 2058)

Nottingham, Nottinghamshire, United Kingdom

Site Status RECRUITING

St James University Hospital ( Site 2055)

Leeds, , United Kingdom

Site Status RECRUITING

Leicester Royal Infirmary ( Site 2051)

Leicester, , United Kingdom

Site Status RECRUITING

The Clatterbridge Cancer Centre ( Site 2069)

Metropolitan Borough of Wirral, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Bulgaria Canada Chile Colombia Finland France Germany Greece Hungary Ireland Israel Italy Japan Netherlands New Zealand Peru Poland Romania Singapore South Korea Spain Sweden Taiwan Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Toll Free Number

Role: CONTACT

Phone: 1-888-577-8839

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://www.merckclinicaltrials.com/

Merck Clinical Trials Information

https://msd.trialsummaries.com/Study/StudyDetails?id=26328&tenant=MT_MSD_9011

Plain Language Summary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-506327-29-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1293-5814

Identifier Type: REGISTRY

Identifier Source: secondary_id

INTerpath-009

Identifier Type: OTHER

Identifier Source: secondary_id

jRCT2061240105

Identifier Type: REGISTRY

Identifier Source: secondary_id

V940-009

Identifier Type: -

Identifier Source: org_study_id